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Abstract
Introduction: Pulmonary hypertension (PH) is the most important prognostic factor after acute pulmonary embolism (PE). The-
refore, determination of patients who will develop PH after acute PE is crucial.  The aim of the present study was to evaluate the 
predictive value of the CHADS2 and CHA2DS2-VASc scores for PH in patients with acute PE.
Material and methods: Seventy-nine adults who presented with acute PE, had an admission systolic pulmonary artery pressure 
(sPAP) measured on echocardiogram and no previous history of PE, were retrospectively identified from the computerized data-
base. 31 patients who had sPAP ≤ 40 mm Hg were categorized as a  “normal pulmonary pressure” group, whereas 48 patients 
who had sPAP > 40 mm Hg were categorized as a “PH” group.
Results: SPAP was > 40 mm Hg in 48 patients (60.8%), with a mean sPAP of 60.9 ± 16.1 mm Hg (median = 60, min–max = 
41–100 mm Hg). In multivariate logistic regression models adjusted for CHADS2 and CHA2DS2-VASc score components, only 
age was found to be related with the development of PH. SPAP was weakly positively correlated with CHADS2 (p = 0.047; r = 
0.224) and CHA2DS2-VASc (p = 0.023; r = 0.256) scores. SPAP values were increasing with the severity of the scores. 
Conclusions: Both CHADS2 and CHA2DS2-VASc scores could be useful in the determination of which patients should be closely 
followed up in order to prevent the development of PH after acute PE.
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Introduction
Acute pulmonary embolism (PE) is one of 
the major causes of mortality, morbidity, and 
hospitalization  worldwide [1]. Since patients 
older than 40 years are at an increased risk 
compared with younger patients, and the risk 
approximately doubles with each subsequent 
decade, an ever-larger number of patients are 
expected to be diagnosed with PE in the future 
[2]. The most important short- and long-term 
complication of PE is pulmonary hypertension 
(PH).  The occurrence of PH after acute PE is 
strongly related with prognosis [3]. Hence, the 
risk stratification of PE to determine the deve-
lopment of PH is crucial.
The CHA2DS2-VASc (congestive heart failure, 
hypertension, age ≥ 75 years, diabetes mellitus, 
previous stroke or transient ischemic attack 
(TIA), vascular disease, age 65 to 74 years, fema-
le gender) score and CHADS2 (congestive heart 
failure, hypertension, age ≥ 75 years, diabetes 
mellitus, previous stroke or TIA) scores are 
used for embolic risk stratification in patients 
with atrial fibrillation (AF) [4]. Recent studies 
have demonstrated that both scores can predict 
prognosis in subjects with stable coronary artery 
disease, acute coronary syndrome and coronary 
artery bypass grafting surgery, irrespective of the 
presence of AF [5–7].
The aim of the present study is to evaluate 
the relation of CHA2DS2-VASc and CHADS2 
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scores with the development of PH in patients 
with acute PE.
Material and methods
In this retrospective study, 79 patients with 
diagnoses of PE were consecutively selected from 
hospital database. The patients’ demographic, 
laboratory and echocardiographic data were ob-
tained from hospital records. The study was in 
compliance with the principles outlined in the 
Declaration of Helsinki and approved by the local 
ethics committee.
Diagnosis of PE was made by an emergency 
department physician, cardiologist and chest 
disease consultant. Thoracal pulmonary compu-
ted tomography angiography (CTA) was perfor-
med to  all the patients. Admission symptoms, 
hemodynamic profile, electrocardiographic fe-
atures and echocardiographic findings were 
obtained from hospital records. The patients’ 
clinical and demographic characteristics, en-
compassing age, gender, history of arterial hy-
pertension, diabetes mellitus, tobacco use, left 
ventricular (LV) ejection fraction and systolic 
pulmonary arterial pressure measurement (sPAP) 
were noted. 
The estimation of sPAP was calculated by 
the peak tricuspid regurgitation velocity (TRV) 
taking into account right atrial pressure (RAP) as 
described by the simplified Bernoulli equation 
[8]. RAP was estimated by echocardiography 
based on the diameter and respiratory variation 
in diameter of the inferior vena cava (IVC): an 
IVC diameter < 2.1 cm that collapses > 50% 
with a sniff suggested a normal RAP of 3 mm 
Table 1. Basic demographic, clinical, laboratory and echocardiographic features of the study population
  Normal pulmonary pressure group 
(n = 31)
Pulmonary hypertension group 
(n = 48)
P
Age 60.2 ± 17.3 64 (22–93) 69.9 ± 14.2 74 (29–88) 0.007*β
Male sex 18 58.10% 25 52.10% 0.602β
Congestive heart failure 3 9.70% 7 14.60% 0.732β
Diabetes 11 35.50% 22 45.80% 0.362β
Hypertension 18 58.10% 28 58.30% 0.981β
Coronary artery disease 17 54.80% 17 35.40% 0.089β
Peripheral artery disease 2 6.50% 5 10.40% 0.698β
Stroke or TIA history 1 3.20% 9 18.80% 0.079β
Hiperlipidemi 10 32.30% 13 27.10% 0.621β
Glucose (mg/dL) 109.6 ± 34.4 98.5 (62–196) 116.6 ± 36.5 106 (69–215) 0.27β
Creatinine (mg/dL) 0.9 ± 0.2 0.9 (0.4–1.4) 1.1 ± 0.5 0.9 (0.6–4.1) 0.481β
Uric acid (mg/dL) 5.5 ± 2 5.4 (2.2–9.2) 7.7 ± 2.8 6.3 (4.6–15.7) 0.01*β
Hemoglobin (g/dL) 12.5 ± 2 12.2 (8.7–15.8) 13.7 ± 11.4 12.1 (7.1–88.9) 0.418β
Platelet count (103/mL) 255.1 ± 84 250 (94–450) 237 ± 89.6 232 (57–419) 0.381β
White blood cell count (103/mL) 7.8 ± 2.3 7.5 (3.4–14.3) 8.2 ± 2.9 7.6 (3.7–19) 0.77β
Troponin I (ng/mL) 1.3 ± 2.7 0.2 (0–8.7) 0.5 ± 0.6 0.2 (0–2.7) 0.797β
CK-MB (mg/L) 24.9 ± 13.7 31 (0.2–40) 28.1 ± 10.1 28 (0.3–48) 0.969β
D-dimer (mcg/L) 5.2 ± 4.7 4.4 (1–24.1) 5.9 ± 5.6 4.3 (0–23) 0.969β
C reactive protein 36.9 ± 33.3 17.2 (4–96) 34.6 ± 29.3 26.1 (0.1–132) 0.728β
LV ejection fraction (%) 55.9 ± 8 60 (30–66) 50.3 ± 12.1 55 (20–65) 0.008*β
SPAP (mm Hg) 34.3 ± 4.2 34 (28–40) 60.9 ± 16.1 60 (41–100) 0.0001*β
CHADS2 score 1.3 ± 1.2 1 (0–5) 2 ± 1.4 2 (0–5) 0.024*β
CHA2DS2-VASc score 2.6 ± 1.9 2 (1–8) 3.5 ± 1.9 3.5 (0–7) 0.015*β
Data are presented as mean ± std deviation, median (min–max values) or number (percentage). *p < 0.05 statistically significant; βIndependent Samples T test; βMann-
Whitney U test; Chi Square Test, CHA2DS2-VASc — congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, previous stroke or transient ischemic 
attack, vascular disease, age 65 to 74 years, female gender; CHADS2 — congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, previous stroke or 
transient ischemic attack; CK-MB — creatinine kinase myoglobin isoform; DVT — deep venous thrombosis; LV — left ventricular; SPAP — systolic pulmonary artery 
pressure; TIA — transient ischemic attack
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Hg (range 0–5 mm Hg), whereas an IVC diameter 
> 2.1 cm that collapses < 50% with a sniff or 
on quiet inspiration suggested a high RAP of 
15 mm Hg (range 10–20 mm Hg). In patients 
in whom the IVC diameter and collapse did 
not fit this paradigm, an intermediate value of 
8 mm Hg (range 5–10 mm Hg) was used. PH was 
defined as an increase in mean pulmonary ar-
terial pressure (mPAP) ≥ 25 mm Hg, and a sPAP 
of 40 mm Hg typically implies a mPAP more than 
25 mm Hg [8].
On the basis of the CHA2DS2-VASc score, pa-
tients were assigned 1 point for congestive heart 
failure, hypertension, age 65–74 years, diabetes 
mellitus, vascular disease, female sex; 2 points 
for age 75 years or older and previous stroke or 
TIA. CHADS2 score was calculated by the sum 
of 1 point for each congestive heart failure, hy-
pertension, age ≥ 75 years, diabetes mellitus and 
2 points for previous stroke or TIA.
Data analysis was performed using SPSS 
Statistics for Windows, version 24.0 (SPSS, Inc., 
Chicago, IL, USA). Kolmogorov-Smirnov and 
Shapiro-Wilk tests were used to examine dist-
ribution pattern. Data were presented as mean 
± standard deviation, median (minimum–maxi-
mum values) for continuous variables. The num-
ber of cases and percentages were used for catego-
rical data. Independent Samples T test was app-
lied for comparisons of data that were normally 
distributed; otherwise the Mann-Whitney U test 
was applied. Categorical data were analyzed using 
the Chi Square test. The effect of each different 
variable on the development of PH was calculated 
in univariate and multivariate analysis. Receiver 
operating characteristics (ROC) curve analysis 
was performed to find the best cut-off points of 
CHADS2 and CHA2DS2-VASc scores for the de-
velopment of PH. P-value <0.05 was considered 
statistically significant.
Results 
A total of 79 patients (mean age: 66.1 
± 16.1 years, 54.4% men) were included in the 
study. Patients were grouped according to sPAP 
values on admission. Thirty-one patients who 
had sPAP ≤ 40 mm Hg were categorized as the 
“normal pulmonary pressure” group, whereas 
48 patients (60.8%) who had sPAP > 40 mm Hg 
were categorized as the “PH” group.
Basic demographic, clinical and laboratory 
parameters of patients are presented in Table 1. 
SPAP value of the normal pulmonary pressure 
group was significantly lower than the pulmonary 
hypertension group (p < 0.0001). CHADS2 and 
CHA2DS2-VASc scores were significantly higher 
in the PH group (p = 0.024; p = 0.015). There 
was no significant difference in terms of PE risk 
factors, including malignancy, surgery, immobi-
lization, pregnancy, deep venous thrombosis and 
travel history (Table 2).
According to univariate logistic regression 
analysis, CHADS2 score [odds ratio (OR): 1.538, 
95% CI 1.043–2.268, p = 0.030], CHA2DS2-VASc 
score (OR: 1.318, 95% CI 1.016–1.711, p = 0.038), 
age (OR: 1.041, 95% CI 1.009–1.073, p = 0.012) 
and LV ejection fraction (OR: 0.939, 95% CI 
0.885–0.997, p = 0.038) were found to be related 
to PH (Table 3). 
In multivariate logistic regression models 
adjusted for CHADS2 and CHA2DS2-VASc score 
components, only age was found to be related 
with the development of PH (OR: 1.037, p = 0.030 
in model 1; OR: 1.041, p = 0.024 in model 2).
ROC curve analysis for CHADS2 and CHA2D-
S2-VASc scores and PH were shown in Figure 1 
and 2. The optimal cut-off value of CHADS2 and 
CHA2DS2-VASc scores for predicting the deve-
lopment of PH were 1.5 and 2.5, respectively in 
ROC curve analysis. Any CHADS2 value greater 
Table 2. Pulmonary embolism risk factors  
Normal pulmonary pressure group 
(n = 31)
Pulmonary hypertension group 
(n = 48)
P
Malignancy n (%) 3 (9.7) 4 (8.3) 1.000
Immobilization n (%) 4 (12.9) 13 (27) 0.134
Surgery n (%) 7 (22.5) 7 (14.5) 0.363
DVT history n (%) 4 (12.9) 1 (2.1) 0.075
Pregnancy n (%) 2 (6.5) 0 0.151
Travel history n (%) 0 1 (2.1) 1.000
DVT — deep venous thrombosis; immobilization — immobilization ≥ 3 days; surgery — surgery in the last month; travel history — travel history > 6 hours in the 
past week
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than 1.5 had a sensitivity of 58%, a specificity of 
58%, and any CHA2DS2-VASc score greater than 
2.5 had a sensitivity of 60% and a spesificity of 
58% to predict the occurrence of PH. 
There was a weak positive correlation be-
tween sPAP and CHADS2 (p = 0.047; r = 0.224) 
and CHA2DS2-VASc (p = 0.023; r = 0.256) scores 
(Figure 3–4). Increased sPAP values were associa-
ted with increased scores. 
Discussion
Acute PE, which is an emergency condition, 
requires precise recognition and timely risk stra-
tification, because early recognition and accurate 
risk stratification determine prognosis [8]. Risk 
stratification in acute PE begins with initial he-
modynamic status assessment at an emergency 
department, being a well-established marker of 
prognosis. It is followed by laboratory tests and 
echocardiographic evaluation. Large and multiple 
emboli abruptly increase pulmonary vascular 
resistance and cause PH which in turn causes 
right ventricular (RV) strain. An acute increase 
of pulmonary pressure is directly related to RV 
Table 3. Univariate and multivariate logistic regression 
analyses to predict pulmonary hypertension
Univariate models Odds 
ratio
95% Confiden-
ce interval
P
Age 1.041 1.009–1.073 0.012
Gender (male) 1.274 0.512–3.167 0.602
Coronary artery disease 0.452 0.180–1.136 0.091
Congestive heart failure 1.593 0.379–6.694 0.525
Hypertension 1.011 0.405–2.526 0.981
Diabetes mellitus 1.538 0.607–3.897 0.364
Peripheral artery disease 1.686 0.306–9.286 0.548
D-dimer (mcg/L) 1.027 0.915–1.152 0.656
Chronic obstructive pul-
monary disease
0.473 0.116–1.920 0.295
LV ejection fraction (%) 0.939 0.885–0.997 0.038
CHADS2 score 1.538 1.043–2.268 0.030
CHA2DS2-VASc score 1.318 1.016–1.711 0.038
Multivariate models
Model 1
Congestive heart failure 1.041 0.219–4.959 0.959
Hypertension 1.668 0.598–4.653 0.328
Age 1.037 1.004–1.071 0.030
Diabetes mellitus 0.687 0.249–1.892 0.467
Stroke history 0.185 0.020–1.683 0.134
Model 2
Congestive heart failure 1.637 0.305–8.777 0.565
Hypertension 1.455 0.494–4.280 0.496
Age 1.041 1.005–1.078 0.024
Diabetes mellitus 0.780 0.259–2.349 0.659
Stroke history 0.125 0.019–1.624 0.125
Coronary artery disease 2.889 0.976–8.551 0.055
Female sex 0.801 0.272–2.354 0.686
ROC Curve
10
AUC = 0.674
95% Cl = 0.523–0.770
p = 0.028
1.0
0.8
0.6
0.4
0.2
0
0 2 4 6 8
1-Specificity
S
e
n
s
it
iv
it
y
Figure 1. Receiver operating characteristic curve analyses of CHADS2 
score for pulmonary hypertension
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Figure 2. Receiver operating characteristic curve analyses of CHA2DS2-
-VASc score for pulmonary hypertension
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myocardial damage, and it is connected with pro-
gnosis [9]. Because of these reasons, estimation of 
pulmonary pressure by invasive or non-invasive 
techniques is important. In the acute setting of PE, 
invasive pulmonary pressure analysis is not an 
easy one, therefore, echocardiographic evaluation 
is the cornerstone of the prognosis assessment. 
Over the past decade, it has been documented 
that sPAP may help estimate mPAP in adults with 
high accuracy and reasonably good precision [10]. 
The 25 mm Hg threshold used to define PH could 
correspond to an sPAP of 38–40 mm Hg [11]. Al-
though the limits of the echocardiographic esti-
mation of sPAP are widely appreciated, the results 
from invasive studies support an evidence-based 
sPAP-derived mPAP value, which is currently 
used to diagnose and follow patients with PH. 
As suggested by these researches, in this study, 
we determined the subjects with PH based on 
echocardiographic sPAP values over 40 mm Hg. 
Chronic thromboembolic pulmonary hyper-
tension (CTEPH) is a clinical entity with high 
pulmonary pressure that occurs after a thrombo-
embolic event. More than 70% of CTEPH patients 
have an history of PE [12]. Therefore, individuals 
with PE should be screened routinely for the 
development of CTEPH.
CHADS2 and CHA2DS2-VASc scores are cli-
nical thromboembolic risk scores for predicting 
stroke in patients from the high-risk population 
and with non-valvular AF [13]. However, recent 
studies have demonstrated that both scores can 
predict mortality in various cardiovascular diseas-
es, irrespective of the presence of AF [14, 15]. In 
our study, the subjects with PH had significantly 
higher CHA2DS2-VASc and CHADS2 scores com-
pared to the normal pulmonary pressure group. 
We found a positive correlation between sPAP 
and CHADS2 and CHA2DS2-VASc scores. Among 
CHA2DS2-VASc score components; age, hyperten-
sion, diabetes mellitus and the presence of vascu-
lar disease are well-known risk factors for deep 
venous thrombosis, which are also the risk factors 
for acute PE [16]. Therefore, these scores may be 
used to  predict the development of PE and PH. 
Although there was a significant difference 
in CHADS2 and CHA2DS2-VASc scores between 
patients with PH and normal pulmonary pressure 
groups, only older age reached  statistical signi-
ficance in multivariate regression analysis. This 
result showed us that the older age is the strongest 
predictor of PH after acute PE. Older age, especial-
ly above 80, is also one of the parameters of Pul-
monary Embolism Severity Index (PESI), which 
is the most reliable and validated risk score sys-
tem after acute PE [17]. The presence of chronic 
heart failure is also a parameter of CHADS2 and 
CHA2DS2-VASc scores, and it is also a component 
of a PESI index. The most recent 2019 European 
Society of Cardiology guidelines for the diagnosis 
and management of acute pulmonary embolism 
developed in collaboration with the European Re-
spiratory Society recommends the determination 
of a clinical risk profile by using PESI index [17]. 
According to our current knowledge, our research 
is the first study using CHADS2 and CHA2DS-
2-VASc scores for risk stratification after acute PE. 
On the other hand, the study has some limi-
tations. First, it has a retrospective cross-sectional 
design with data from a single center. Due to the 
retrospective nature of our data and the small 
sample size, our findings can not be generalized 
Figure 3. Correlation between systolic pulmonary artery pressure and 
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Figure 4. Correlation between systolic pulmonary artery pressure and 
CHA2DS2-VASc score
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to all populations. Second, pulmonary pressure 
estimation and determination of patients with PH 
were done with echocardiography. Invasive right 
heart catheterization was not performed. Finally, 
sPAP measurements were used instead of mPAP, 
which might have led to misdiagnosis of PH. 
Conclusions
In our study, older age is the most important 
factor related to the development of PH after 
acute PE. Both CHADS2 and CHA2DS2-VASc 
scores could be useful in acute PE setting in the 
determination of which patients should be closely 
followed up so that more prolonged anticoagu-
lation therapy and surveillance concerning the 
development of PH may be applied. 
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